<?xml version="1.0" encoding="UTF-8"?>
<p>The COVID-19 is the third novel coronavirus to cause a large-scale epidemic in the twenty-first century after the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) in 2003 [
 <xref rid="B8-pathogens-09-00331" ref-type="bibr">8</xref>,
 <xref rid="B9-pathogens-09-00331" ref-type="bibr">9</xref>,
 <xref rid="B10-pathogens-09-00331" ref-type="bibr">10</xref>] and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in 2012 [
 <xref rid="B11-pathogens-09-00331" ref-type="bibr">11</xref>,
 <xref rid="B12-pathogens-09-00331" ref-type="bibr">12</xref>,
 <xref rid="B13-pathogens-09-00331" ref-type="bibr">13</xref>]. Our knowledge and experience in fighting the previous two epidemics can be used for creating treatment strategies against this pandemic. Recently, different medications and a combination of drugs have shown promising results. For example, the combination of chloroquine and azithromycin [
 <xref rid="B14-pathogens-09-00331" ref-type="bibr">14</xref>]. Furthermore, the antiviral drug remdesivir and the malaria drug chloroquine have gained much attention globally as potential medications for COVID-19 treatment. On the other hand, different companies are working on finding a treatment in a creative method, antiviral RNA, for example [
 <xref rid="B15-pathogens-09-00331" ref-type="bibr">15</xref>].
</p>
